NASDAQ:LMNX

Luminex (LMNX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$36.99
$36.99
50-Day Range
$36.66
$37.01
52-Week Range
$20.61
$41.69
Volume
N/A
Average Volume
873,093 shs
Market Capitalization
$1.75 billion
P/E Ratio
72.53
Dividend Yield
1.08%
Price Target
N/A
LMNX stock logo

About Luminex Stock (NASDAQ:LMNX)

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; and TDAS, an analysis program designed for development and optimization of nucleic acid assays. The company also provides xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism; ARIES system, a sample to answer real-time PCR platform; SYNCT data management software solutions; and ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 Assay, ARIES Flu A/B & RSV Assay, ARIES Group B Streptococcus Assay, ARIES Group A Strep Assay, ARIES Bordetella Assay, ARIES Norovirus Assay, ARIES C. difficile Assay, ARIES MRSA Assay, and SARS-CoV-2 Assay. In addition, it offers VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market; VERIGENE test cartridges; Amnis FlowSight imaging flow cytometers; Amnis ImageStream Mark II imaging flow cytometers; Amnis CellStream for cell and particle analysis; Guava easyCyte benchtop flow cytometers; Muse cell analyzers; and IDEAS, an image analysis software. Luminex Corporation was founded in 1995 and is based in Austin, Texas.

LMNX Stock News Headlines

A new way to collect income from stocks
Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…
Luminex Resources Corp (LR)
Luminex (LMNX) Receives FDA Approval for NxTAG RPP
A new way to collect income from stocks
Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…
Luminex Announces an Update on the Pegasus Earn-in
Luminex Ltd.
Cincinnati company Luminex’s SPAC deal collapses
Luminex Announces Results of Shareholder Meeting
See More Headlines
Receive LMNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Luminex and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/07/2021
Today
4/24/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & Medical Instruments
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:LMNX
CUSIP
55027E10
Fax
N/A
Employees
1,325
Year Founded
N/A

Profitability

Net Income
$15.17 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$417.40 million
Cash Flow
$1.12 per share
Book Value
$11.13 per share

Miscellaneous

Free Float
N/A
Market Cap
$1.75 billion
Optionable
Optionable
Beta
0.56
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Nachum Shamir (Age 67)
    Chairman, CEO & Pres
    Comp: $1.91M
  • Mr. Harriss T. Currie (Age 59)
    CFO, Sr. VP of Fin. & Treasurer
    Comp: $824.12k
  • Mr. Richard W. Rew II (Age 53)
    Sr. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer
    Comp: $693.94k
  • Mr. Todd C. Bennett (Age 51)
    Sr. VP of Global Sales & Customer Operations
    Comp: $660.42k
  • Mr. Randall J. Myers (Age 59)
    Sr. VP of Global Manufacturing & Quality
    Comp: $633.57k
  • Mrs. Kendel B. Martin CPA
    VP of Accounting
  • Jeff Christensen
    Sr. Director of Investor Relations
  • Mr. Eric S. Shapiro (Age 57)
    Sr. VP of Global Marketing
  • Ms. Nancy M. Fairchild (Age 67)
    Sr. VP of HR
  • Dr. Charles J. Collins (Age 44)
    Sr. VP of R&D

LMNX Stock Analysis - Frequently Asked Questions

How were Luminex's earnings last quarter?

Luminex Co. (NASDAQ:LMNX) announced its quarterly earnings data on Sunday, February, 7th. The medical instruments supplier reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.13 by $0.12. The medical instruments supplier earned $111.39 million during the quarter, compared to the consensus estimate of $104.57 million. Luminex had a trailing twelve-month return on equity of 4.66% and a net margin of 5.39%. The firm's revenue for the quarter was up 23.1% compared to the same quarter last year. During the same period last year, the company earned $0.07 EPS.
Read the conference call transcript
.

Is Luminex a good dividend stock?

Luminex (NASDAQ:LMNX) pays an annual dividend of $0.40 per share and currently has a dividend yield of 1.08%. The dividend payout ratio is 125.00%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, LMNX will have a dividend payout ratio of 33.33% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for LMNX.

What is Nachum “Homi” Shamir's approval rating as Luminex's CEO?

53 employees have rated Luminex Chief Executive Officer Nachum “Homi” Shamir on Glassdoor.com. Nachum “Homi” Shamir has an approval rating of 87% among the company's employees.

What other stocks do shareholders of Luminex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Luminex investors own include NVIDIA (NVDA), Baidu (BIDU), Cisco Systems (CSCO), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Micron Technology (MU), Block (SQ), Marvell Technology (MRVL), AbbVie (ABBV) and CRISPR Therapeutics (CRSP).

This page (NASDAQ:LMNX) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners